SciSparc

About

Funding history · 8 rounds · $73.5M total

Headcount over time

Offices

Q&A

What is SciSparc's primary focus as a biopharmaceutical company?

SciSparc is a clinical-stage biopharmaceutical company that focuses on developing cannabinoid-based pharmaceuticals for central nervous system disorders, including Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's disease and agitation, Autism Spectrum Disorder, epilepsy, and pain.

When did SciSparc (formerly Therapix Biosciences) go public on NASDAQ?

SciSparc went public on NASDAQ in March 2017.

What was the total amount raised by SciSparc through funding rounds?

SciSparc has raised a total of $63,756,000 through various public offerings.

What was SciSparc's most recent public offering amount and date?

SciSparc's most recent completed public offering was in August 2023, raising $1,300,000.

What was the amount of SciSparc's public offering in May 2023?

In May 2023, SciSparc completed a public offering that raised $1,729,964.

What is one of SciSparc's key product candidates?

One of SciSparc's key product candidates is SCI-110, which is being developed for the treatment of Tourette Syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation.

Has SciSparc been granted any patents recently?

In March 2024, SciSparc was granted another patent, strengthening its core technology in Canada.

What was a significant development in SciSparc's autism spectrum disorder clinical trial in March 2024?

In March 2024, SciSparc achieved a major milestone with the first patient dosed in its Autism Spectrum Disorder clinical trial.

Team · 21

Oz Adler

Chief Executive Officer and Chief Financial Officer

Adi Zuloff-Shani

Chief Technologies Officer

Itschak Shrem

Chairman of the Board

Amitay Weiss

President and Director

Liat Sidi

Director

Moshe Revach

Director

Lior Vider

Director

Amnon Ben Shay

External Director

Alon Dayan

External Director

Professor Raphael Mechoulam

Professor Emeritus of the Department of Natural Products of the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem

Dr. Yossi Tam

Director of the Hebrew University’s Multidisciplinary Center on Cannabinoid Research

Prof. James Leckman

Neison Harris Professor of Child Psychiatry, Psychiatry, Psychology and Pediatrics at Yale University

Dr. Michael H. Bloch

Associate Training Director of the Child Study Center’s Solnit Integrated Program

David Nutt

Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London

Prof. Davis Mellar

Board-certified and fellowship-trained specialist in hospice and palliative medicine in Geisinger Medical System Danville, PA

Prof. Kirsten Müller-Vahl

Professor of Psychiatry at the Department of Psychiatry, Social psychiatry and Psychotherapy at the Hanover Medical School, Germany

Prof. Daniele Piomelli

Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry at University of California, Irvine

Prof. Michael Davidson

Chairman of the Stuckinski Centre for Alzheimer’s Disease Research in Ramat Gan, Israel

Prof. Saoirse O’Sullivan

Professor

Prof. Avi Weizman

Professor of Child and Adult Psychiatry at the Sackler Faculty of Medicine of Tel Aviv University

Prof. Elon Eisenberg

Dean of the Faculty of Medicine at the Technion – Israel Institute of Technology

Sectors & technology

Highlights

Tags